Tavr Market Size, Share, Industry Trends and Forecast to 2030

TAVR Market Size & CAGR in 2021

The transcatheter aortic valve replacement (TAVR) market size in 2021 was valued at USD 5.4 billion, with a compound annual growth rate (CAGR) of 12.5% from 2021 to 2028. The market is expected to reach USD 9.7 billion by 2028, driven by the increasing prevalence of aortic stenosis and the rising adoption of minimally invasive procedures.

COVID-19 Impact on the TAVR Market

The COVID-19 pandemic had a significant impact on the TAVR market, leading to the postponement of non-essential procedures and a decline in hospital admissions for cardiac conditions. However, as healthcare systems adapted to the new normal, the TAVR market began to recover, with an increase in procedures and a growing acceptance of telemedicine for patient consultations.

TAVR Dynamics

The TAVR market is driven by technological advancements in valve design, increasing reimbursement for TAVR procedures, and growing awareness among patients about the benefits of minimally invasive treatments. The market is also influenced by the aging population, which is more prone to aortic valve diseases, and the preference for TAVR over traditional surgical options.

Segments and Related Analysis

The TAVR market can be segmented based on the approach (transfemoral, transapical, transaortic, transsubclavian), valve type (balloon-expandable, self-expandable), and end-user (hospitals, ambulatory surgical centers). Each segment offers unique opportunities for market growth, with transfemoral TAVR being the most commonly performed approach.

By Region Analysis

Regionally, North America currently dominates the TAVR market, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. The market growth in these regions is driven by the presence of well-established healthcare infrastructure, increasing prevalence of aortic valve diseases, and advancements in TAVR technology.

Key Market Players and Competitive Landscape

The key players in the TAVR market include Edwards Lifesciences Corporation, Medtronic Plc, Boston Scientific Corporation, Abbott Laboratories, and JenaValve Technology, Inc. These companies are focused on product innovation, strategic collaborations, and geographic expansion to gain a competitive edge in the market.

Recent Happenings in the TAVR Market

In recent developments, Edwards Lifesciences received FDA approval for its SAPIEN 3 Ultra transcatheter heart valve for the treatment of aortic stenosis. Medtronic announced the launch of its Evolut PRO+ TAVR system with advanced sealing technology. Abbott received CE Mark approval for its Tendyne transcatheter mitral valve replacement system, expanding its presence in the TAVR market.